Wil Helmus schreef op 12 maart 2019 12:30:
That ability to treat multiple forms of hypoglycemia makes dasiglucagon a compound with a
billion-dollar-a-year market potential if it passes its phase 3 trials.
...........with readout in H1 2019 and with an expected New Drug Application (NDA) filing H2 2019.
Nog een paar maandjes geduld, dan gaat dit aandeel knallen